Immunoprecise Antibodies Net Worth
Immunoprecise Antibodies Net Worth Breakdown | IPA |
Immunoprecise Antibodies Net Worth Analysis
Immunoprecise Antibodies' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Immunoprecise Antibodies' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Immunoprecise Antibodies' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Immunoprecise Antibodies' net worth analysis. One common approach is to calculate Immunoprecise Antibodies' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Immunoprecise Antibodies' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Immunoprecise Antibodies' net worth. This approach calculates the present value of Immunoprecise Antibodies' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Immunoprecise Antibodies' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Immunoprecise Antibodies' net worth. This involves comparing Immunoprecise Antibodies' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Immunoprecise Antibodies' net worth relative to its peers.
To determine if Immunoprecise Antibodies is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immunoprecise Antibodies' net worth research are outlined below:
| Immunoprecise Antibodies had very high historical volatility over the last 90 days | |
| Immunoprecise Antibodies has some characteristics of a very speculative penny stock | |
| Immunoprecise Antibodies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 24.52 M. Reported Net Loss for the year was (27.18 M) with profit before taxes, overhead, and interest of 12.1 M. | |
| Immunoprecise Antibodies has about 19.24 M in cash with (4.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immunoprecise Antibodies has a frail financial position based on the latest SEC disclosures |
Immunoprecise Antibodies uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immunoprecise Antibodies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunoprecise Antibodies' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 8th of July 2024 Next Financial Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View | |
| 8th of July 2024 Next Fiscal Year End | View | |
| 31st of October 2023 Last Quarter Report | View | |
| 30th of April 2023 Last Financial Announcement | View |
Follow Immunoprecise Antibodies' market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 15.07 M.Project Immunoprecise Antibodies' profitablity
The company has Net Profit Margin of (1.16) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.46) %, which entails that for every $100 of revenue, it lost $0.46.When accessing Immunoprecise Antibodies' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Immunoprecise Antibodies' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immunoprecise Antibodies' profitability and make more informed investment decisions.
Please note, the presentation of Immunoprecise Antibodies' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immunoprecise Antibodies' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Immunoprecise Antibodies' management manipulating its earnings.
Immunoprecise Antibodies time-series forecasting models is one of many Immunoprecise Antibodies' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunoprecise Antibodies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Immunoprecise Antibodies Earnings per Share Projection vs Actual
Immunoprecise Antibodies Corporate Management
| Kari Graber | Vice Services | Profile | |
| Brad McConn | Chief Officer | Profile | |
| Barry Duplantis | VP Relations | Profile | |
| Ilse Roodink | Chief Officer | Profile | |
| David Orton | Chief Officer | Profile | |
| Joseph Scheffler | Interim Officer | Profile | |
| Roland Romijn | Head IPA | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.